Abbott on Thursday forecast third-quarter profit below Wall Street expectations and estimated about $200 million in annual tariff costs.

Abbott beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices, including continuous glucose monitors.